ChemPartner PharmaTech Co Ltd (300149) — Net Asset Quality Index
ChemPartner PharmaTech Co Ltd (300149) has a Net Asset Quality Index of 64.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.04 Billion minus total liabilities of CN¥728.59 Million yields net assets of CN¥1.31 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See ChemPartner PharmaTech Co Ltd (300149) liquidity interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
ChemPartner PharmaTech Co Ltd Net Asset Quality Index Over Time (2007–2025)
This chart shows how ChemPartner PharmaTech Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 64.3%, representing net assets of CN¥1.31 Billion against total assets of CN¥2.04 Billion CNY. Explore 300149 cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for ChemPartner PharmaTech Co Ltd (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for ChemPartner PharmaTech Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 300149 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 64.0% | CN¥1.30 Billion | CN¥2.03 Billion | CN¥732.59 Million | ▲ +1.9 pp |
| 2024 | 62.0% | CN¥1.24 Billion | CN¥2.00 Billion | CN¥757.75 Million | ▲ +2.0 pp |
| 2023 | 60.0% | CN¥1.46 Billion | CN¥2.43 Billion | CN¥973.44 Million | ▼ -2.4 pp |
| 2022 | 62.4% | CN¥2.39 Billion | CN¥3.82 Billion | CN¥1.44 Billion | ▲ +15.2 pp |
| 2021 | 47.2% | CN¥1.99 Billion | CN¥4.22 Billion | CN¥2.23 Billion | ▼ -12.3 pp |
| 2020 | 59.5% | CN¥2.45 Billion | CN¥4.12 Billion | CN¥1.67 Billion | ▼ -1.6 pp |
| 2019 | 61.1% | CN¥2.30 Billion | CN¥3.77 Billion | CN¥1.46 Billion | ▼ -4.7 pp |
| 2018 | 65.9% | CN¥2.20 Billion | CN¥3.35 Billion | CN¥1.14 Billion | ▼ -14.2 pp |
| 2017 | 80.1% | CN¥835.45 Million | CN¥1.04 Billion | CN¥207.73 Million | ▼ -17.0 pp |
| 2016 | 97.1% | CN¥769.93 Million | CN¥793.16 Million | CN¥23.23 Million | ▲ +1.3 pp |
| 2015 | 95.7% | CN¥723.81 Million | CN¥756.00 Million | CN¥32.19 Million | ▲ +1.8 pp |
| 2014 | 94.0% | CN¥696.53 Million | CN¥741.13 Million | CN¥44.60 Million | ▼ -1.2 pp |
| 2013 | 95.2% | CN¥670.29 Million | CN¥703.99 Million | CN¥33.70 Million | ▼ -0.8 pp |
| 2012 | 96.0% | CN¥640.90 Million | CN¥667.61 Million | CN¥26.72 Million | ▼ -0.5 pp |
| 2011 | 96.5% | CN¥611.46 Million | CN¥633.82 Million | CN¥22.37 Million | ▼ -0.8 pp |
| 2010 | 97.3% | CN¥571.30 Million | CN¥587.42 Million | CN¥16.12 Million | ▲ +23.0 pp |
| 2009 | 74.3% | CN¥101.26 Million | CN¥136.30 Million | CN¥35.04 Million | ▲ +7.2 pp |
| 2008 | 67.1% | CN¥58.36 Million | CN¥86.93 Million | CN¥28.57 Million | ▲ +31.4 pp |
| 2007 | 35.8% | CN¥24.25 Million | CN¥67.79 Million | CN¥43.53 Million | — |